Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay.


Journal

Cancer cytopathology
ISSN: 1934-6638
Titre abrégé: Cancer Cytopathol
Pays: United States
ID NLM: 101499453

Informations de publication

Date de publication:
02 2019
Historique:
received: 01 08 2018
revised: 13 10 2018
accepted: 18 10 2018
pubmed: 1 12 2018
medline: 15 11 2019
entrez: 1 12 2018
Statut: ppublish

Résumé

Evaluation of programmed cell death ligand 1 (PD-L1) expression can be made on both resection specimens and diagnostic biopsies; however, more than 30% of patients with advanced non-small cell lung cancer (NSCLC) do not have adequate histologic material to perform PD-L1 assays and require additional biopsies. In addition, in our practice, more than 16% of cases have cytological smears as the only available material. Our aim was to validate the PD-L1 immunocytochemistry assay on cytological smears and compare its accuracy with the results obtained from tissue cores and whole tumor sections using the clinically relevant cutoff of 50%. We compared the PD-L1 staining results of cytological smears to those from tissue cores or whole sections in 50 and 53 NSCLC cases, respectively, using the SP263 assay after scanning hematoxylin and eosin slides. We found an overall agreement of 90.6% between cytological smears and whole sections; specifically, we found absolute concordance between smears with PD-L1 expressed in <10% and ≥50% of cells and whole sections with PD-L1 expressed in <50% and ≥50% of cells, respectively. In addition, slightly lower diagnostic accuracy was found for the cytological smears in comparison with the tissue cores, but the difference was not statistically significant. We found excellent intraobserver and good interobserver agreement in the evaluation of PD-L1 on smears. Immunocytochemistry on cytological smears is a reliable method for determination of PD-L1 at the 50% cutoff when positive cells are <10% or ≥50%; for cases showing PD-L1 expression in 10% to 49% of cells, additional tissue sampling may be necessary.

Sections du résumé

BACKGROUND
Evaluation of programmed cell death ligand 1 (PD-L1) expression can be made on both resection specimens and diagnostic biopsies; however, more than 30% of patients with advanced non-small cell lung cancer (NSCLC) do not have adequate histologic material to perform PD-L1 assays and require additional biopsies. In addition, in our practice, more than 16% of cases have cytological smears as the only available material. Our aim was to validate the PD-L1 immunocytochemistry assay on cytological smears and compare its accuracy with the results obtained from tissue cores and whole tumor sections using the clinically relevant cutoff of 50%.
METHOD
We compared the PD-L1 staining results of cytological smears to those from tissue cores or whole sections in 50 and 53 NSCLC cases, respectively, using the SP263 assay after scanning hematoxylin and eosin slides.
RESULTS
We found an overall agreement of 90.6% between cytological smears and whole sections; specifically, we found absolute concordance between smears with PD-L1 expressed in <10% and ≥50% of cells and whole sections with PD-L1 expressed in <50% and ≥50% of cells, respectively. In addition, slightly lower diagnostic accuracy was found for the cytological smears in comparison with the tissue cores, but the difference was not statistically significant. We found excellent intraobserver and good interobserver agreement in the evaluation of PD-L1 on smears.
CONCLUSION
Immunocytochemistry on cytological smears is a reliable method for determination of PD-L1 at the 50% cutoff when positive cells are <10% or ≥50%; for cases showing PD-L1 expression in 10% to 49% of cells, additional tissue sampling may be necessary.

Identifiants

pubmed: 30500997
doi: 10.1002/cncy.22083
doi:

Substances chimiques

Antigens, Neoplasm 0
B7-H1 Antigen 0
CD274 protein, human 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

52-61

Informations de copyright

© 2018 American Cancer Society.

Auteurs

Enrico Munari (E)

Department of Pathology, Sacro Cuore Don Calabria Hospital, Negrar, Italy.

Giuseppe Zamboni (G)

Department of Pathology, Sacro Cuore Don Calabria Hospital, Negrar, Italy.
Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Giorgia Sighele (G)

Department of Pathology, Sacro Cuore Don Calabria Hospital, Negrar, Italy.

Marcella Marconi (M)

Department of Pathology, Sacro Cuore Don Calabria Hospital, Negrar, Italy.

Marco Sommaggio (M)

Department of Pathology, Sacro Cuore Don Calabria Hospital, Negrar, Italy.

Gianluigi Lunardi (G)

Department of Oncology, Sacro Cuore Don Calabria Hospital, Negrar, Italy.

Giulio Rossi (G)

Department of Pathology, AUSL della Romagna, Ravenna, Italy.

Alberto Cavazza (A)

Department of Pathology, Arcispedale S. Maria Nuova/IRCCS, Reggio Emilia, Italy.

Francesca Moretta (F)

Department of Laboratory Medicine, Sacro Cuore Don Calabria Hospital, Negrar, Italy.

Eliana Gilioli (E)

Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Anna Caliò (A)

Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

George J Netto (GJ)

Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama.

Mohammad O Hoque (MO)

Department of Otolaryngology, Urology, Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Guido Martignoni (G)

Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Department of Pathology, Pederzoli Hospital, Peschiera del Garda, Italy.

Matteo Brunelli (M)

Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Paola Vacca (P)

Immunology Research Area, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy.

Lorenzo Moretta (L)

Immunology Research Area, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy.

Giuseppe Bogina (G)

Department of Pathology, Sacro Cuore Don Calabria Hospital, Negrar, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH